Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an announcement.
Shanghai Fosun Pharmaceutical announced that its subsidiary, Jinzhou Avanc Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the drug registration of Fovinaciclib Citrate Capsules. This new drug is intended for use in combination with Fulvestrant to treat adult patients with hormone receptor-positive and HER2-negative recurrent or metastatic breast cancer, marking a significant step in the company’s oncology portfolio and potentially enhancing its market position in cancer treatment solutions.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company incorporated in China, operating in the pharmaceutical industry. The company focuses on the development and manufacturing of pharmaceuticals, with a market emphasis on innovative drug solutions.
Average Trading Volume: 4,628,611
Technical Sentiment Signal: Hold
Current Market Cap: HK$62.5B
See more insights into 2196 stock on TipRanks’ Stock Analysis page.